| Signaling pathways in cancer metabolism: mechanisms and therapeutic targets M You, Z Xie, N Zhang, Y Zhang, D Xiao, S Liu, W Zhuang, L Li, Y Tao Signal transduction and targeted therapy 8 (1), 196, 2023 | 119 | 2023 |
| Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients X Yang, B Chen, Y Wang, Y Wang, J Long, N Zhang, J Xue, Z Xun, ... Hepatology International 17 (3), 709-719, 2023 | 46 | 2023 |
| Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma N Zhang, X Yang, M Piao, Z Xun, Y Wang, C Ning, X Zhang, L Zhang, ... Biomarker Research 12 (1), 26, 2024 | 27 | 2024 |
| Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma YY Wang, X Yang, YC Wang, JY Long, HS Sun, YR Li, ZY Xun, N Zhang, ... World Journal of Gastroenterology 29 (10), 1614, 2023 | 21 | 2023 |
| Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer C Zhu, J Xue, Y Wang, S Wang, N Zhang, Y Wang, L Zhang, X Yang, ... Frontiers in Immunology 14, 1109292, 2023 | 21 | 2023 |
| Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma … C Zhu, H Li, X Yang, S Wang, Y Wang, N Zhang, Y Wang, J Xue, L Zhang, ... Cancer Immunology, Immunotherapy 72 (9), 2949-2960, 2023 | 16 | 2023 |
| High incidence combination of multiple primary malignant tumors of the digestive system XB Yang, LH Zhang, JN Xue, YC Wang, X Yang, N Zhang, D Liu, ... World Journal of Gastroenterology 28 (41), 5982, 2022 | 16 | 2022 |
| Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors R Guan, N Zhang, M Deng, Y Lin, G Huang, Y Fu, Z Zheng, W Wei, ... International Journal of Surgery 110 (7), 4062-4073, 2024 | 14 | 2024 |
| Radiation therapy with combination therapy of immune checkpoint inhibitors and antiangiogenic therapy for hepatocellular carcinoma C Ning, X Zhang, Y Wang, X Yang, X Yang, J Chao, Z Xun, J Xue, Y Wang, ... International Journal of Radiation Oncology* Biology* Physics 118 (5), 1461-1471, 2024 | 13 | 2024 |
| Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma X Yang, B Lian, N Zhang, J Long, Y Li, J Xue, X Chen, Y Wang, Y Wang, ... BMC medicine 22 (1), 42, 2024 | 13 | 2024 |
| Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade B Sun, Z Xun, N Zhang, K Liu, X Chen, H Zhao Cancer Cell International 23 (1), 313, 2023 | 11 | 2023 |
| A Composite Biomarker of Derived Neutrophil–Lymphocyte Ratio and Platelet–Lymphocyte Ratio Correlates With Outcomes in Advanced Gastric Cancer Patients Treated With Anti-PD-1 … Y Pan, H Si, G Deng, S Chen, N Zhang, Q Zhou, ZK Wang, G Dai Frontiers in Oncology 11, 798415, 2022 | 10 | 2022 |
| Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer C Zhu, Y Wang, R Zhu, S Wang, J Xue, D Zhang, Z Lan, C Zhang, Y Liang, ... Biomarker Research 12 (1), 56, 2024 | 9 | 2024 |
| Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC Y Wang, N Zhang, J Xue, C Zhu, Y Wang, L Zhang, X Yang, H Wang, ... Frontiers in Immunology 14, 1084843, 2023 | 7 | 2023 |
| Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis J Chao, S Wang, H Wang, N Zhang, Y Wang, X Yang, C Zhu, C Ning, ... Cancer Immunology, Immunotherapy 72 (11), 3717-3726, 2023 | 6 | 2023 |
| Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer Y Wang, Z Xun, X Yang, Y Wang, S Wang, J Xue, N Zhang, X Yang, Z Lu, ... American Journal of Cancer Research 13 (3), 1026, 2023 | 6 | 2023 |
| A composite indicator of derived neutrophil–lymphocyte ratio and lactate dehydrogenase correlates with outcomes in pancreatic carcinoma patients treated with PD-1 inhibitors S Chen, S Guo, M Gou, Y Pan, M Fan, N Zhang, Z Tan, G Dai Frontiers in oncology 12, 951985, 2022 | 5 | 2022 |
| Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti‐PD‐1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic … Y Pan, H Si, R Jia, G Deng, H Yan, M Fan, M Gou, S Chen, N Zhang, ... Journal of Oncology 2022 (1), 1427779, 2022 | 5 | 2022 |
| Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study Y Wang, X Yang, Y Wang, J Xue, N Zhang, X Yang, N Cong, J Zhang, ... Cancer Immunology, Immunotherapy 72 (7), 2197-2204, 2023 | 4 | 2023 |
| Prognostic value of SAT volume and density for predicting the outcome of patients with unresectable HCC treated with lenvatinib plus anti-PD-1 antibodies J Zhang, X Yang, X Yang, J Xu, Y Wang, Y Wang, Z Xun, N Zhang, ... American Journal of Cancer Research 13 (3), 912, 2023 | 4 | 2023 |
